Signadori Bio is developing a next-generation, off-the-shelf immunotherapy approach that engineers monocytes in vivo to regulate and enhance myeloid anti-tumour activity. The company’s lead programme is SiB-2101, which it is advancing toward lead candidate nomination. Its platform and scientific approach are based on research conducted at Gustave Roussy and were developed by founders Dr Jean-Luc Perfettini and Professor Nathalie Chaput. Signadori is preclinical-stage and is based in Paris. Financially, the company has raised a total of €11.1 million following the recent seed extension, with backing from Sofinnova Partners, Invivo Partners, and new participation from Taiho Ventures. The company intends to use the funds to further develop its proprietary platform and to expand its scientific and operational teams to move toward clinical translation.

Total raised

$13M

Funding rounds

2

Latest round

Seed

Latest activity

May 2026